47 minutes ago
Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.
48 minutes ago
The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.
49 minutes ago
PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.
50 minutes ago
Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.
51 minutes ago
APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.